Best practices: Appropriate use of the new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa

Best practices: Appropriate use of the new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa

Antibiotic stewardship of hospital-acquired infections because of difficult-to-treat resistant (DTR) Gram-negative bacteria is a global challenge. Their increasing prevalence in South Africa has required a shift in prescribing in recent years towards colistin, an antibiotic of last resort. High toxi...

Full description

Bibliographic Details
Main Authors:	Adrian J. Brink, Jennifer Coetzee, Guy A. Richards, Charles Feldman, Warren Lowman, Hafsah D. Tootla, Malcolm G.A. Miller, Abraham J. Niehaus, Sean Wasserman, Olga Perovic, Chetna N. Govind, Natalie Schellack, Marc Mendelson
Format:	Article
Language:	English
Published:	AOSIS 2022-10-01
Series:	Southern African Journal of Infectious Diseases
Subjects:	antimicrobial stewardship β-lactam/β-lactamase inhibitor combinations ceftazidime-avibactam ceftolozane-tazobactam gram-negatives pseudomonas aeruginosa enterobacterales
Online Access:	https://sajid.co.za/index.php/sajid/article/view/453

Similar Items

In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane/tazobactam and ceftazidime/avibactam
by: Wantin Sribenjalux, et al.
Published: (2022-03-01)

Treatment of bone and joint infections by ceftazidime/avibactam and ceftolozane/tazobactam: a cohort study
by: Claire Rempenault, et al.
Published: (2021-06-01)

Ceftolozane/Tazobactam and Ceftazidime/Avibactam for Multidrug-Resistant Gram-Negative Infections in Immunocompetent Patients: A Single-Center Retrospective Study
by: Rosario Cultrera, et al.
Published: (2020-09-01)

Evaluation of In Vitro Activity of Ceftolozane-tazobactam and Ceftazidime-avibactam Against Carbapenemase-producing Multi-drug Resistant Klebsiella pneumoniae Isolates
by: Hüseyin Agah TERZİ, et al.
Published: (2020-12-01)

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections
by: Helio S. Sader, et al.
Published: (2021-12-01)

Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital
by: C. Weber, et al.
Published: (2022-10-01)

SUSCETIBILIDADE DE ISOLADOS DE ENTEROBACTEREALES RESISTENTE AOS CARBAPENÊMICOS AOS ANTIBIÓTICOS CEFTAZIDIMA-AVIBACTAM, CEFTOLOZANE-TAZOBACTAM E CEFIDEROCOL
by: Deise Reis Carvalho, et al.
Published: (2023-10-01)

Combined Resistance to Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Extensively Drug-Resistant (XDR) and Multidrug-Resistant (MDR) <i>Pseudomonas aeruginosa</i>: Resistance Predictors and Impact on Clinical Outcomes Besides Implications for Antimicrobial Stewardship Programs
by: Marianna Meschiari, et al.
Published: (2021-10-01)

First Study of Antimicrobial Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against Pseudomonas aeruginosa Isolated from Patients with Urinary Tract Infection in Tehran, Iran
by: Rahimzadeh M, et al.
Published: (2020-02-01)

Evaluation of in Vitro Activity of Ceftazidime/Avibactam and Ceftolozane/Tazobactam against ESBL-producing Enterobacterales Isolated from Intensive Care Units from Qatar
by: Mazen A. Sid Ahmed, et al.
Published: (2022-09-01)

Comparison of antimicrobial activity between ceftolozane–tazobactam and ceftazidime–avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa
by: Adnan Alatoom, et al.
Published: (2017-09-01)

Evaluation of in-vitro susceptibility of ß-lactam-resistant Gram-negative bacilli to ceftazidime-avibactam and ceftolozane-tazobactam from clinical samples of a general hospital in southern Brazil
by: Thaisa Noceti Carvalho, et al.
Published: (2023-01-01)

Susceptibility of Meropenem-Resistant and/or Carbapenemase-Producing Clinical Isolates of <i>Enterobacterales</i> (<i>Enterobacteriaceae</i>) and <i>Pseudomonas aeruginosa</i> to Ceftazidime-Avibactam and Ceftolozane-Tazobactam as Assessed by In Vitro Testing Methods
by: Venere Cortazzo, et al.
Published: (2022-07-01)

Association of <i>bla</i><sub>VIM-2</sub>, <i>bla</i><sub>PDC-35</sub>, <i>bla</i><sub>OXA-10,</sub> <i>bla</i><sub>OXA-488</sub> and <i>bla</i><sub>VEB-9</sub> β-Lactamase Genes with Resistance to Ceftazidime–Avibactam and Ceftolozane–Tazobactam in Multidrug-Resistant <i>Pseudomonas aeruginosa</i>
by: Mazen A. Sid Ahmed, et al.
Published: (2022-01-01)

Extensively drug-resistant Pseudomonas aeruginosa: clinical features and treatment with ceftazidime/avibactam and ceftolozane/tazobactam in a tertiary care university hospital center in Portugal – A cross-sectional and retrospective observational study
by: Diogo Mendes Pedro, et al.
Published: (2024-02-01)

In Vitro Activities of Ceftazidime–Avibactam and Aztreonam–Avibactam at Different Inoculum Sizes of Extended-Spectrum β-Lactam-Resistant Enterobacterales Blood Isolates
by: Moonsuk Bae, et al.
Published: (2021-12-01)

Susceptibility of multi-drug resistant isolates of Pseudomonas aeruginosa to ceftazidime/aviabactam and ceftolozane/tazobactam in Benha University Hospital in Egypt and detection of carbapenemase genes
by: Sahar Fayed, et al.
Published: (2023-08-01)

Evaluation of ceftolozane-tazobactam susceptibility on a French nationwide collection of Enterobacterales
by: Agnès B. Jousset, et al.
Published: (2023-03-01)

Whole Genome Sequencing of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Resistant Pseudomonas aeruginosa Isolated from a Blood Stream Infection Reveals VEB and Chromosomal Metallo-Beta Lactamases as Genetic Determinants: A Case Report
by: Alamri AM, et al.
Published: (2020-11-01)

Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)
by: Thitima Kongnakorn, et al.
Published: (2019-12-01)

Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences
by: Marianna Criscuolo, et al.
Published: (2020-02-01)

Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo
by: Zeyu Huang, et al.
Published: (2023-11-01)

Ceftazidime-avibactam susceptibility among KPC-producing enterobacterales in southern Brazil
by: Natália Kehl Moreira, et al.
Published: (2023-11-01)

Clinical and microbiological features of ceftolozane/tazobactam-resistant Pseudomonas aeruginosa isolates in a university hospital in central Italy
by: Gianluca Morroni, et al.
Published: (2022-09-01)

In Vitro Activity of Auranofin in Combination With Aztreonam-Avibactam Against Metallo-β-lactamase (MBL)-Producing Enterobacterales
by: Wen Wang, et al.
Published: (2021-10-01)

Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
by: María José Contreras-Gómez, et al.
Published: (2022-10-01)

Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018
by: Dee Shortridge, et al.
Published: (2022-12-01)

Increased zinc levels facilitate phenotypic detection of ceftazidime-avibactam resistance in metallo-β-lactamase-producing Gram-negative bacteria
by: Michaela Simon, et al.
Published: (2022-11-01)

In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula
by: Ágnes Sonnevend, et al.
Published: (2020-10-01)

The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations
by: Abdullah Tarık Aslan, et al.
Published: (2022-02-01)

Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis
by: Maxwell J. Lasko, et al.
Published: (2021-01-01)

Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacterales: A Multi-Center Study in Southwest China
by: Sun S, et al.
Published: (2022-04-01)

Role of Enzymatic Activity in the Biological Cost Associated with the Production of AmpC β-Lactamases in Pseudomonas aeruginosa
by: Isabel M. Barceló, et al.
Published: (2022-10-01)

The <i>Klebsiella pneumoniae</i> carbapenemase (KPC) β-Lactamase Has Evolved in Response to Ceftazidime Avibactam
by: Sona Garsevanyan, et al.
Published: (2023-12-01)

Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps
by: Joseph Terracciano, PhD, et al.
Published: (2017-01-01)

Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019
by: James A. Karlowsky, et al.
Published: (2021-03-01)

Antimicrobial activity of cephalosporin–beta-lactamase inhibitor combinations against drug-susceptible and drug-resistant Pseudomonas aeruginosa strains
by: Amani M. Alnimr, PhD, et al.
Published: (2020-06-01)

Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Enterobacterales Bloodstream Infection: a Systematic Review and Meta-Analysis
by: Yan Chen, et al.
Published: (2022-04-01)

Evaluation of in vitro activity of ceftolozane-tazobactam in combination with other classes of antibacterial agents against Enterobacterales and Pseudomonas aeruginosa—the EM200 study
by: J. Belkhair, et al.
Published: (2021-05-01)

A Simple Disk Stacking Plus Micro-Elution Method for Rapid Detection of the Synergistic Effect of Aztreonam and Ceftazidime/Avibactam Against Metallo-β-Lactamase Producing Enterobacterales
by: Liu Z, et al.
Published: (2023-03-01)